Historically, many solid-dose medications were distributed in bulk glass or high-density plastic bottles. However, as global pharmaceutical standards evolve, the industry is witnessing a continuous and massive shift toward unit-dose blister packaging. This transition is driven by the urgent need to protect sensitive formulations from degradation, enhance patient safety, and streamline manufacturing efficiency.
While glass and plastic bottles have been traditional staples, they present inherent flaws for modern pharmaceuticals. Every time a patient opens a bulk bottle, the entire remaining contents are exposed to ambient air, humidity, and potential contaminants. Over time, this repeated exposure can lead to the deliquescence (moisture absorption) and mildew of sensitive solid preparations, ultimately compromising drug efficacy and shelf life.
Compared to bulk packaging, blister packs offer a highly engineered, patient-centric solution. Industry analysts confirm that the proportion of blister packaging in the pharmaceutical sector will continue to soar due to several distinct advantages:
As the demand for blister packaging rises, so does the need for highly efficient manufacturing processes. Driven by rising global labor costs and the strict demands of cGMP compliance, pharmaceutical manufacturers are rapidly phasing out standalone, manual packaging operations.
Integrating Blistering Machines and Cartoners into a seamless, fully automated production line has become the industry gold standard. These integrated blister lines not only slash labor expenses but also eliminate human error, minimize material waste, and ensure a synchronized workflow from primary sealing to secondary cartoning.
As a leader dedicated to pharma blister packaging machines since 1986, Jornen is at the forefront of this shift, continuously delivering flexible, high-speed integrated solutions to help pharmaceutical companies worldwide meet the growing demand for premium blister packaging.